In summary, if BIM deletion was associated with imatinib-resistance, the common BIM deletion would become a symbol of excluded imatinib for treating CML in East-Asian. The gene discussed is BCL2L11; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.